Ultragenyx Reports Fourth Quarter and Full Year 2021 Financial Results and Corporate Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Needham Starts NeoVolta (NEOV) at Buy
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Ultragenyx Pharma (RARE) Misses Q4 EPS by 45c
February 10, 2022 4:30 PM ESTUltragenyx Pharma (NASDAQ: RARE) reported Q4 EPS of ($1.79), $0.45 worse than the analyst estimate of ($1.34). Revenue for the quarter came in at $83.4 million versus the consensus estimate of $83.79 million.
GUIDANCE:
The company expects 2022 revenue for Crysvita in Ultragenyx territories to be... More
